Nurix Therapeutics's 15min chart shows KDJ Death Cross and Bearish Marubozu.

The 15-minute chart of Nurix Therapeutics recently displayed a KDJ Death Cross and a Bearish Marubozu at 09/04/2025 13:15. This technical indicator suggests that the momentum of the stock price has shifted towards the downside, with a potential for further decrease in value. Sellers currently dominate the market, and it is likely that this bearish momentum will continue.

Title: Nurix Therapeutics (NRIX) Faces Bearish Momentum as Technical Indicators Signal Downward Trend

September 02, 2025

The 15-minute chart of Nurix Therapeutics (NRIX) recently displayed a KDJ Death Cross and a Bearish Marubozu at 09/04/2025 13:15. These technical indicators suggest a shift in the stock's momentum towards the downside, with a potential for further decrease in value. Sellers currently dominate the market, and it is likely that this bearish momentum will continue.

Technical Indicators Analysis

KDJ Death Cross:
The KDJ (K Moving Average, J Moving Average, D Moving Average) indicator is a momentum oscillator that helps identify trends and potential reversals. The KDJ Death Cross occurs when the K line crosses below the D line, indicating a bearish signal. This event was observed on 09/04/2025, suggesting a potential reversal in the stock's upward trend.

Bearish Marubozu:
A Bearish Marubozu is a candlestick pattern that indicates a strong bearish trend. It is characterized by a long body with no upper or lower shadows, suggesting that the stock price moved lower throughout the entire period. The presence of a Bearish Marubozu on 09/04/2025 supports the bearish sentiment indicated by the KDJ Death Cross.

Recent Company Developments

Despite the bearish technical indicators, Nurix Therapeutics has reported significant progress in recent quarters. In Q2 2025, the company reported a revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. The company's drug bexobrutideg (NX-5948) showed impressive clinical results, with an 80.9% objective response rate in r/r CLL patients [2].

Investor Conference Participation

To keep investors informed, Nurix Therapeutics has announced its participation in multiple investor conferences during September 2025. The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website [1].

Market Sentiment

The bearish momentum indicated by the technical indicators may impact investor sentiment. As of August 27, 2025, the stock price of Nurix Therapeutics (NRIX) was $9.55, and the market cap was not specified [1]. Investors should closely monitor the stock's performance and consider the potential implications of the recent technical signals.

Conclusion

While Nurix Therapeutics has shown promising clinical results and financial growth, the recent technical indicators suggest a potential downward trend in the stock's value. Investors should remain vigilant and consider the implications of these signals when making investment decisions.

References

[1] https://www.stocktitan.net/news/NRIX/
[2] https://www.stocktitan.net/news/NRIX/